HormoneFDA Approved

Macimorelin (Macrilen)

Oral

Overview

An orally bioavailable growth hormone secretagogue approved as a diagnostic agent for adult growth hormone deficiency (AGHD). Macimorelin stimulates GH release via GHS-R1a agonism, and the GH response to a standardized oral dose is used to confirm or exclude AGHD.

Mechanism of Action

It offers a simpler, better-tolerated alternative to the insulin tolerance test and GHRH-arginine test for GH deficiency diagnosis..

Research Summary & Key Findings

FDA-approved in 2017 as a diagnostic test for AGHD. Demonstrated 87% sensitivity and 96% specificity in clinical validation studies compared to the insulin tolerance test. Single oral dose produces measurable GH peak within 30-90 minutes. Well-tolerated with dysgeusia being the most common side effect (Garcia et al., J Clin Endocrinol Metab, 2018).

Clinical Status

FDA Approved

Macimorelin (Macrilen) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Oral

Related Peptides in Hormone

Find a Provider

Find a verified provider who offers Macimorelin (Macrilen) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Macimorelin (Macrilen).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.